COA Bedtime Story Hour

The vendor certificate of analysis has replaced Goodnight Moon in the nightly reading rotation.

Filed under Survodutide ·Cagrilintide ·Tesofensine · #stack-life ·#cope ·#vendor-culture

Active Compounds

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

Cagrilintide · Amylin Analogue

A long-acting amylin analogue being developed in combination with semaglutide (CagriSema) for enhanced weight loss.

Tesofensine · Monoamine Reuptake Inhibitor

A triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine) that produced up to 10.6% weight loss in Phase 2 trials — roughly double the efficacy of older appetite suppressants. Approved in Mexico; not yet FDA-approved.

RX: Survodutide · Cagrilintide · Tesofensine
Dosage: one PDF nightly
Half-life: until next batch
Source: manual
Tags: stack-life , cope , vendor-culture
Stamped: 2026-07-02 · Cycle 027
Lot #: LOT-20260702T13:39:26.354Z